Bio-Techne Corporation (TECH)
Bio-Techne Corporation (TECH) M&A Call Transcript
Bio-Techne Corporation (TECH) M&A Call Transcript
CMB.TECH: A Stronger Shipping Platform, But Not A Cheap One
CMBT.TECH transformed post-Golden Ocean merger, evolving from a tanker-focused play to a diversified shipping platform with over 250 vessels. Current tanker and dry bulk markets are both robust, driving strong Q1 2026 results, but investors now face multi-cycle risk exposure. Q1 profit of $368.8M was boosted by $267.4M in vessel disposals, reflecting proactive capital management amid favorable market conditions.
Why Is Techne (TECH) Up 4.5% Since Last Earnings Report?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript
CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript
CMB.TECH Q1 Earnings Call Highlights
CMB.TECH NYSE: CMBT reported a strong first quarter of 2026, with management highlighting higher revenue, reduced leverage, lower financing costs and substantial gains from vessel sales during an earnings call titled “Firing on All Cylinders.”
Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript
Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript
TECH Stock Falls on Q3 Earnings & Revenue Miss, Operating Margin Up
Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.
Techne (TECH) Misses Q3 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.
All You Need to Know About Techne (TECH) Rating Upgrade to Buy
Techne (TECH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CMB.TECH: Valuation Implies Mid-Cycle - Reality Looks Stronger
CMB.TECH is now a highly leveraged play on freight rates, with over 80% spot exposure post-merger and tripled operating scale. Reported EPS is distorted by one-off Golden Ocean deal costs; normalized earnings and EBITDA provide a clearer view of CMBT's true earnings power. CMBT's valuation and investment case hinge on freight rate sensitivity, with current market cap implying mid-to-high cycle TCE rates ($35k–45k/day).
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.
Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?
Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The position was previously 2.3% of the fund's AUM as of the prior quarter.
